不对称二甲基精氨酸与心血管相关疾病发病机制的研究进展

郭紫轩; 刘运洪; 彭传梅; 王杨; 卫波; 高辉

doi:10.13201/j.issn.1001-1439.2017.08.003

不对称二甲基精氨酸与心血管相关疾病发病机制的研究进展

- 1 昆明医科大学附属延安医院检验科(昆明, 650051);
- 2 中国科学院深圳先进技术研究院
基金项目:
云南省应用基础研究 (昆医联和专项) (No:2015FB089)

昆明医科大学2017年研究生创新基金 (No:2017S150)

详细信息

通讯作者: 高辉,E-mail:459820005@qq.com

中图分类号: R543

收稿日期: 2017-04-27

Research progress between Asymmetric Dimethylarginine and cardiovascular disease pathogenesis

- 1 Department of Clinical Laboratory, Yanan Hospital Affiliated to Kunming Medical University, Kunming, 650051, China;
- 2 Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences

More Information

Corresponding author: GAO Hui, E-mail: 459820005@qq.com

Received Date: 27 April 2017

摘要

摘要: 心血管疾病已成为我国乃至全球面临的重大疾病之一。不对称二甲基精氨酸(ADMA)是内源性一氧化氮合酶(NOs)的抑制剂,竞争抑制一氧化氮(NO)的产生,诱发氧化应激反应,引起血管内皮功能不全,导致心血管疾病的发生发展。现已发现ADMA是心血管疾病新的独立预测因子及危险因素,本文对ADMA在心血管相关疾病的调控机制,以及其作为一种新的标志物在心血管相关疾病诊断中的研究进展进行综述。
- 不对称二甲基精氨酸 /
- 一氧化氮 /
- 心血管疾病
Abstract: Cardiovascular disease has become one of the major diseases that our country and even the whole world faces. Two asymmetric dimethylarginine (ADMA) is an endogenous nitric oxide synthase (NOs) inhibitor, competitive inhibition of nitric oxide (NO) production induced oxidative stress caused by vascular endothelial dysfunction, leading to the development of cardiovascular disease. It has been found that ADMA is the independent predictor of cardiovascular disease risk and new factors, the regulation mechanism of ADMA in cardiovascular related diseases, as well as a new marker in the diagnosis of cardiovascular disease related research progress are reviewed in this article.
- Asymmetric Dimethylarginine /
- nitric oxide /
- cardiovascular disease

HTML全文

参考文献(38)

[1]	CO A S, MOZAFFARIAN D, ROGER V L, et al.Heart disease and stroke statistics-2014update:a report from the American Heart Association[J].Circulation, 2014, 129:28-292.
[2]	BOURAS G, DEFTEREOS S, TOUSOULIS D, et al.Asymmetric Dimethylarginine (ADMA):apromising biomarker for cardiovascular disease?[J].Curr Top Med Chem, 2013, 13:180-200.
[3]	BALDWIN R M, MORETTIN, COTE J.Role of PRMTs in cancer:could minor isoforms be leaving a mark?[J].Woeld J Biol Chem, 2014, 5:115-129.
[4]	HU X, ATZLER D, XU X, et al.Global DDAH1gene deficient mice reveal that DDAH1is the critical enzyme for degrading the cardiovascular risk factor ADMA[J].Arterioscler Thromb Vasc Bool, 2011, 31:1540-1546.
[5]	RODIONOV R N, MARTENSLOBENHOFFER J, BRILLOFF S, et al.Abstract 18457:acetylation of asymmetric dimethylarginine-a novel pathway of clearance of endogenous methylarginines[J].Circulation, 2014, 130:A18457-A18457.
[6]	RODIONOV R N, MARTENS-LOBENHOFFER J, BRILLOFF S, et al.Acetylation of asymmetric and symmetric dimethylarginine:an undercharacterized pathway of metabolism of endogenous methylarginines[J].Nephrol Dial Transplant, 2016, 31:57-63.
[7]	MARTENS-LOBENHOFFER J, RODIONOV R N, BODE-BOGER S M.Probong AGXT2enzyme activity in mouse tissue by applying stable isotopelabeled asymmetric dimethyl as substrate[J].J Mass Spectrom, 2012, 47:1594-1600.
[8]	RODINOV R N, BURDIN D, BRILLOFF S, et al.Endothelium, vascular tone and nitric oxide:endothelial dysfunction[J].Circulation, 2015, 132:A17603.
[9]	RODINOV R N, MARTENS-LOBENHOFFER J, BRILLOF S, et al.Role of alanine:glyoxylate aminotransferase 2in metabolism of asymmetric dimethylarginine in the settings of asymmetric dimethylarginine overload and bilateral nephrectomy[J].Nephrol DialTransplant, 2014, 29:2035-2042.
[10]	CHEN L, ZHOU J P, KUANG D B, et al.4-HNE increases intracellular ADMA levels in cuitured HUVECs:Evidence for miR-21-dependent mechanisms[J].PLoS ONE, 2013, 8:e64148.
[11]	XUAN C, LUN L M, ZHAO J X, et al.L-citrulline for protection of endothelial function from ADMA-induced injury in porcine coronary artery[J].Scientific Reports, 2015, 5:10987-10988.
[12]	MCCARTY M F.Asymmetric dimethylarginine is a well established mediating risk factor for cardiovascular morbidity and mortality-should patients with elevated levels be supplemented with citrulline?[J].Healthcare, 2016, 4:40-52.
[13]	WILLOUGHBY S R, RAJENDRAN S, CHAN W P, et al.Ramipril sensitizes platelets to nitric oxide:implications for therapy in high-risk patients[J].Am Coll Cardiol, 2012, 60:887-894.
[14]	WILLEIT P, FREITAG D F, LAUKKANEN J A, et al.Asymmetric dimethylarginine and cardiovascular risk:systematic review and meta-analysis of 22prospective studies[J].J Am Heart Assoc, 2015, 4:e001833.
[15]	王丽平.microRNAs在心肌梗死中的研究进展[J].临床心血管病杂志, 2016, 32 (3):217-220.
[16]	RICCIONI G, SCOTTI L, D'ORAZIO N, et al.ADMA/SDMA in elderly subjects with asymptomatic carotid atherosclerosis:values and site-specific association.[J].Int J Mol Sci, 2014, 15:6391-6398.
[17]	JIANG N, WANG M, SONG J, et al.N-methylnicotinamide protects against endothelial dysfunction and attenuates atherogenesis in apolipoprotein E-deficient mice[J].Mol Nutr Food Res, 2016, 115:287-287.
[18]	HAISSMAN J M, HAUGAARD A K, KNUDSEN A, et al.Marker of endothelial dysfunction asymmetric dimethylarginine is elevated in HIV infection but not associated with sub-clinical atherosclerosis[J].J Acquir Immune Defic Syndr, 2016, 73:507-513.
[19]	MANGIACAPRA F, CONTE M, DEMARTINI C, et al.Relationship of asymmetric dimethylarginine (ADMA) with extent and functional severity of coronary atherosclerosis.[J].Int J Cardiol, 2016, 220:629-633.
[20]	HUANG S, ZOU D, PENG W, et al.The prediction roles of asymmetric dimethyl-arginine, adiponectin and apelin for macroangiopathy in patients with impaired glucose regulation[J].Ann Dendocrinol, 2016, 220:630-632.
[21]	BORGERAAS H, HERTEL J K, SVINGEN G F, et al.Association between Body Mass Index, Asymmetric Dimethylarginine and Risk of Cardiovascular Events and Mortality in Norwegian Patients with Suspected Stable Angina Pectoris[J].PLoS One, 2016, 11:e0152029.
[22]	XUAN C, TIAN Q W, LI H, et al.Levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, and risk of coronary artrtery disease:a meta-analysis based on 4713participants[J].Eur J Prev Cardiol, 2016, 23:502-510.
[23]	INAN B, ATES I, OZKAYAR N, et al.Are increased oxidative stress and asymmetric dimethylarginine levels associated with masked hypertension?[J].Clin Exp Hypertens, 2016, 38:1-9.
[24]	RAPTIS V, KAPOULAS S, GREKAS D.Role of asymmetrical dimethylarginine in the progression of renal disease[J].Nephrology, 2013, 18:11-21.
[25]	AST J, JABECKA A, BOGDANSKI P, et al.Evaluation of antihypertensive effect of l-arginine supplementation in patients with mild hypertension assessed with ambulatory blood pressure monitoring[J].Pharmacol Rep, 2010, 62:73-75.
[26]	SEEMA L J, AARTI K, ANIL B.Risk of cardiovascular diseases in diabetes mellitus and serum concentration of asymmetrical dimethylarginine[J].Biochem Res Int, 2013, 9:189-430.
[27]	JAWALEKAR S L, KARNIK A, BHUTEY A.Risk of cardiovascular disease in disease mellitus and serum concentration of asymmetrical dimethylarginine[J].Boochem Res Int, 2013, 32:189430-189431.
[28]	HUS C P, HUS P F, CHUNG M Y, et al.Asymmetric dimethylarginine and long-term adverse cardiovascular events in patients with type 2diabetes:relation with glycemic control[J].Cardiovascular Diabetol, 2014, 13:156-165.
[29]	PONIEDZIALEK-CZAJKOWSKA E, MIERZYNSKI R, SZYMULA D, et al.Intercellular adhesion molecule and endogenous NOS inhibitor:asymmetric dimethylarginine in pregnant women with gestational diabetes mellitus[J].J Diabet Res, 2016, 2016:1-5.
[30]	ALPOIM P N, SOUSA L P N, MOTA A P L, et al.Asymmetric Dimethylarginine (ADMA) in cardiovascular and renal disease[J].Clin Chim Acta, 2014, 440C:36-39.
[31]	BENITO S, SÁNCHEZ A, UNCETA N, et al.LCQTOF-MS-based targeted metabolomics of argininecreatine metabolic pathway-related compounds in plasma:application to identify potential biomarkers in pediatric chronic kidney disease[J].Anal Bioanal Chem, 2016, 408:1-14.
[32]	BRIET M, BURNS K D.Chronic kidney disease and vascular remodeling:molecular mechanisms and clinical implications[J].Clin Sci (Lond), 2012, 123:399-416.
[33]	RAPTIS V, KAPOULAS S, GREKAS D.Role of asymmetrical dimethylarginine in the progression of renal disease[J].Nephrology (Carlton), 2013, 18:11-21.
[34]	EISELT J, RAJDL D, RACEK J, et al.Asymmetric dimethylarginine and progression of chronic kidney disease-a one-year follow-up study[J].Kidney Blood Press Res, 2014, 39:50-57.
[35]	BAYLIS C.Nitric oxide synthase derangements and hypertension in kidney disease[J].Curr Opin Nephrol Hypertens, 2012, 21:1-6.
[36]	PASAOGLU O T, TURKOZKAN N, ARK M, et al.The effect of taurine on the relationship between NO, ADMA and homocysteine in endotoxin-mediated inflammation in HUVEC cultures[J].Inflammation, 2014, 5:1439-1443.
[37]	SANDOO A, DIMITROULAS T, HODSON J, et al.Cumulative inflammation associates with asymmetric dimethylarginine in rheumatoid arthritis:a 6year follow-up study[J].Rheumatology (Oxford), 2015, 54:1145-1152.
[38]	朱科, 张军平, 李萌.神经型一氧化氮合酶在冠心病中的研究进展[J].临床心血管病杂志, 2017, 33 (3):207-210.